BR112015028884A2 - tratamento ou prevenção de depressão utilizando mentol e/ou icilina - Google Patents

tratamento ou prevenção de depressão utilizando mentol e/ou icilina

Info

Publication number
BR112015028884A2
BR112015028884A2 BR112015028884A BR112015028884A BR112015028884A2 BR 112015028884 A2 BR112015028884 A2 BR 112015028884A2 BR 112015028884 A BR112015028884 A BR 112015028884A BR 112015028884 A BR112015028884 A BR 112015028884A BR 112015028884 A2 BR112015028884 A2 BR 112015028884A2
Authority
BR
Brazil
Prior art keywords
iciline
menthol
treating
preventing depression
depression
Prior art date
Application number
BR112015028884A
Other languages
English (en)
Inventor
Markram Henry
Le Coutre Johannes
Pezzoli Maurizio
Michlig Gonzalez Stéphanie
Camacho Susana
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112015028884A2 publication Critical patent/BR112015028884A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
    • C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
    • C07C35/12—Menthol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

resumo patente de invenção: "tratamento ou prevenção de depressão utilizando mentol e/ou icilina". a presente invenção refere-se a composições para tratamento ou prevenção de depressão, e as composições contêm uma quantidade terapeuticamente eficaz de um composto selecionado do grupo que consiste em mentol, icilina e suas combinações. métodos para tratamento ou prevenção de depressão estão também providos, e os métodos incluem administrar tais composições.
BR112015028884A 2013-05-24 2014-05-23 tratamento ou prevenção de depressão utilizando mentol e/ou icilina BR112015028884A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827256P 2013-05-24 2013-05-24
PCT/EP2014/060634 WO2014187943A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of depression using menthol and/or icilin

Publications (1)

Publication Number Publication Date
BR112015028884A2 true BR112015028884A2 (pt) 2017-07-25

Family

ID=50841770

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015028884A BR112015028884A2 (pt) 2013-05-24 2014-05-23 tratamento ou prevenção de depressão utilizando mentol e/ou icilina

Country Status (8)

Country Link
US (1) US20160108005A1 (pt)
EP (1) EP3003294A1 (pt)
JP (1) JP2016524609A (pt)
CN (1) CN105263481A (pt)
AU (1) AU2014270339A1 (pt)
BR (1) BR112015028884A2 (pt)
CA (1) CA2908378A1 (pt)
WO (1) WO2014187943A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007134107A2 (en) * 2006-05-10 2007-11-22 Janssen Pharmaceutica N.V. Cold menthol receptor-1 antagonists
PA8790401A1 (es) * 2007-07-18 2009-03-31 Janssen Pharmaceutica Nv Sulfonamidas como moduladores de trpm8
US8217060B2 (en) * 2009-05-15 2012-07-10 Janssen Pharmaceutica, Nv Benzimidazole derivatives useful as TRP M8 receptor modulators
US20120172429A1 (en) * 2009-07-10 2012-07-05 Woolf Clifford J Permanently charged sodium and calcium channel blockers as anti- inflammatory agents
JP2012193176A (ja) * 2011-03-03 2012-10-11 Nippon Zoki Pharmaceut Co Ltd ミルナシプラン含有経皮吸収用医薬組成物
CN102258751A (zh) * 2011-07-21 2011-11-30 泰一和浦（北京）中医药研究院有限公司 用于治疗忧郁症、消愁解忧、善解抑郁的中药薄荷
JP5376481B1 (ja) * 2013-03-04 2013-12-25 日本臓器製薬株式会社 経皮吸収用医薬組成物

Also Published As

Publication number Publication date
EP3003294A1 (en) 2016-04-13
WO2014187943A1 (en) 2014-11-27
US20160108005A1 (en) 2016-04-21
CA2908378A1 (en) 2014-11-27
CN105263481A (zh) 2016-01-20
AU2014270339A1 (en) 2015-10-08
JP2016524609A (ja) 2016-08-18

Similar Documents

Publication Publication Date Title
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
BR112016007462A2 (pt) fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite
BR112014019399A2 (pt) métodos de tratamento da fibrose
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112016026470A8 (pt) composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2516 DE 26-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]